Table 3.

Oral HPV16 DNA and Baseline Prevalence of HPV16 E6 and E7 Seropositivity in the Persistence Oral Papillomavirus Study

	n=264	HPV16 E6	Unadjusted OR (95%CI)#	Adjusted OR (95% CI)^#	HPV16 E7	Unadjusted OR (95%CI)#	Adjusted OR (95% CI)~#
Overall	264	7.6% (n=20)`	---	---	3.4% (n=9)`	---	---
Oral HPV16 DNA- throughout study	176	6.3%	REF	REF	2.8%	REF	REF
Oral HPV16 DNA+ in study	88	10.2%	1.7 (0.68–4.3)	2.0 (0.55–6.9)	4.6%	1.6 (0.43–6.2)	2.0 (0.52–7.9)

^{^}Adjusted for age, gender, smoking status, number of recent and lifetime oral sex partners, HIV/CD4 status, and study site

^~Adjusted only for age, smoking status, HIV/CD4 status as other covariates were collinear

^#Oral HPV16 DNA’s association with HPV16 E6 and E7 seropositivity was measured through logistic regression

^`When seropositvity was defined as an OD five standard deviations above the mean OD in the control cohort), there were six E6+ individuals (prevalence=2.3%), and three E7+ individuals (prevalence=1.1%). However was still no association for either E6 or E7 seropositivity with HPV16